| Literature DB >> 33883022 |
Danielle Talita Dos Santos1, Luiz Henrique Arroyo1, Yan Mathias Alves2, Luana Seles Alves2, Thais Zamboni Berra2, Juliane de Almeida Crispim3, Josilene Dália Alves4, Denisse Andrea Cartagena Ramos5, Jonas Bodini Alonso1, Ivaneliza Simionato de Assis6, Antônio Vieira Ramos2, Elma Mathias Dessunti7, Ione Carvalho Pinto2, Pedro Fredemir Palha2, Ricardo Alexandre Arcêncio8, Carla Nunes9.
Abstract
BACKGROUND: A diagnosis of tuberculosis (TB) does not mean that the disease will be treated successfully, since death may occur even among those who are known to the health services. Here, we aimed to analyze patient survival time from the diagnosis of TB to death, precocious deaths, and associated factors in southern Brazil.Entities:
Keywords: HIV; Mortality; Risk factors; Survival analysis; Tuberculosis
Year: 2021 PMID: 33883022 PMCID: PMC8058757 DOI: 10.1186/s41182-021-00320-4
Source DB: PubMed Journal: Trop Med Health ISSN: 1348-8945
Independent variables under study
| Categories | Independent variables | Classes |
|---|---|---|
| Socio-demographic characteristicsa | Gender | Female |
| Male | ||
| Age | Continuous | |
| Ethnicity | White/oriental | |
| Afrodescendant | ||
| Educational level | 8 years of schooling or more | |
| 7 years of schooling or less | ||
| Marital status | Married/common-law marriage | |
| Single/widowed/separated or divorced | ||
| Comorbiditiesb | Type of entry | New case |
| Re-entry or retreatment | ||
| Institutionalized | No | |
| Yes | ||
| Examination: X-ray | Normal | |
| Yes, suspicious results | ||
| Clinical category | Pulmonary | |
| Extrapulmonary | ||
| Aggravation—use of alcohol | No | |
| Yes | ||
| Aggravation— | No | |
| Yes | ||
| Information of the diagnosis and treatmentb | Examination: bacilloscopy | Negative |
| Positive | ||
| Culture | Negative | |
| Positive | ||
| Medication used: rifampicin | Yes | |
| No | ||
| Medication used: isoniazid | Yes | |
| No | ||
| Medication used: pyrazinamide | Yes | |
| No | ||
| Medication used: ethambutol | Yes | |
| No | ||
| Medication used: streptomycin | Yes | |
| No | ||
| Medication used: other drugs (second-line TB drugs) | Yes | |
| No | ||
| Supervised treatment—DOTS | Yes | |
| No |
aVariables from the first database Mortality Information System Sistema de Informação sobre Mortalidade (SIM)
bVariables from the second database Sistema de Informação de Agravos de Notificação (SINAN)
Fig. 1Flow chart of deaths analyzed in the study
Characteristics of the patients who died due to TB, Curitiba-Brazil
| Variables | Categories | All deaths | |
|---|---|---|---|
| (%) | |||
| Coinfection (basic cause)a | Yes (TB/HIV) | 62 | 42.5 |
| No (only TB) | 84 | 57.5 | |
| Gender (14)a | Female | 32 | 21.9 |
| Male | 114 | 78.1 | |
| Ethnicity (133)a | White or oriental | 96 | 65.8 |
| Afrodescendant | 40 | 27.4 | |
| Not reported | 10 | 6.8 | |
| Years of schoolinga | 0-7 years of schooling | 84 | 57,5 |
| 8 or more years of schooling | 42 | 28,8 | |
| Not reported | 20 | 13.7 | |
| Marital statusa | Married/common-law marriage | 46 | 31.5 |
| Single/widowed/separated or divorced | 84 | 57.5 | |
| Not reported | 16 | 11.0 | |
| Type of entryb | New case | 122 | 83.6 |
| Re-entry or retreatment | 24 | 16.4 | |
| Not reported | 0 | 0 | |
| Inpatient treatmentb | No | 115 | 78.8 |
| Yes | 16 | 11.0 | |
| Not reported | 15 | 10.2 | |
| X-ray confirmation of diagnosisb | No | 22 | 15.1 |
| Yes/suspicious | 124 | 84.9 | |
| Clinical formb | Pulmonary | 106 | 72.6 |
| Extrapulmonary | 40 | 27.4 | |
| Alcoholismb | No | 90 | 61.7 |
| Yes | 50 | 34.2 | |
| Not reported | 06 | 4.1 | |
| Diabetes mellitus (DM)b | No | 136 | 93.1 |
| Yes | 03 | 2.1 | |
| Not reported | 07 | 4.8 | |
| Microscopyb | Negative | 40 | 27.4 |
| Positive | 81 | 55.5 | |
| Not reported | 25 | 17.1 | |
| Sputum culture (40)b | Negative | 20 | 13.7 |
| Positive | 20 | 13.7 | |
| Not reported | 106 | 72.6 | |
| Rifampicinb | No | 06 | 4.1 |
| Yes | 128 | 87.7 | |
| Not reported | 12 | 8.2 | |
| Isoniazidb | No | 06 | 4.1 |
| Yes | 128 | 87.7 | |
| Not reported | 12 | 8.2 | |
| Pyrazinamideb | No | 06 | 4.1 |
| Yes | 128 | 87.7 | |
| Not reported | 12 | 8.2 | |
| Ethambutolb | No | 37 | 25.3 |
| Yes | 97 | 66.5 | |
| Not reported | 12 | 8.2 | |
| Streptomycinb | No | 131 | 89.7 |
| Yes | 03 | 2.1 | |
| Not reported | 12 | 8.2 | |
| Ethionamideb | No | 132 | 90.4 |
| Yes | 01 | 0.7 | |
| Not reported | 13 | 8.9 | |
| Medication used: other drugsb | No | 122 | 83.6 |
| Yes | 07 | 4.8 | |
| Not reported | 17 | 11.6 | |
| Directly observed therapy (DOT)b | No | 18 | 12.3 |
| Yes | 114 | 78.1 | |
| Not reported | 14 | 9.6 | |
aVariables from the first database Mortality information system Sistema de Informação sobre Mortalidade (SIM)
bVariables from the second database Sistema de Informação de Agravos de Notificação (SINAN)
Survival time according to each factor considered for the Cox proportional hazards regression model, Curitiba-Brazil
| Explanatory variables | Mean of survival time (days) | Standard deviation of survival time (days) | First quartile of survival time (Q1) | Second quartile of survival time (Q2) | Third quartile of survival time (Q3) | Maximum survival time | |
|---|---|---|---|---|---|---|---|
| Type of entry | |||||||
| New case | 122 | 47.89 | 67.83 | 7.00 | 21.00 | 60.25 | 349 |
| Relapse | 24 | 200.96 | 384.39 | 20.75 | 80.50 | 127.50 | 1688 |
| TB/HIV coinfection | |||||||
| No | 84 | 48.44 | 79.66 | 7.00 | 21.00 | 58.75 | 513 |
| Yes | 62 | 106.39 | 248.89 | 9.25 | 36.50 | 100.50 | 1688 |
| Alcoholism | |||||||
| No | 90 | 70.40 | 123.24 | 9.25 | 27.00 | 87.50 | 1008 |
| Yes | 50 | 78.92 | 246.31 | 7.25 | 23.50 | 49.75 | 1688 |
| Gender | |||||||
| Female | 32 | 69.72 | 114.64 | 7.75 | 21.00 | 65.75 | 513 |
| Male | 114 | 73.98 | 188.55 | 8.00 | 25.00 | 81.00 | 1688 |
| Clinical form | |||||||
| Pulmonary | 106 | 77.01 | 199.48 | 7.25 | 23.50 | 77.00 | 1688 |
| Extrapulmonary | 40 | 62.55 | 78.55 | 8.75 | 24.50 | 91.25 | 310 |
Fig. 2Curves obtained from the Kaplan-Meier survival analysis of the explanatory variables in patients who died of TB, Curitiba-Brazil. Legend: dispersion time according to age and survival
Fig. 3Interaction plots for each pair of explanatory variables according to survival time, Curitiba-Brazil
Results of the Cox proportional hazards regression model of patients who died from TB and associated factors, Curitiba-Brazil
| Explanatory variables | Coefficient | Hazard ratio | 95% CI | |
|---|---|---|---|---|
| Type of entry | ||||
| New case | 1 | 1 | ||
| Relapse | −0.98 | 0.37 | 0.22-0.63 | < 0.01 |
| TB/HIV coinfection | ||||
| No | 1 | 1 | ||
| Yes | 0.43 | 1.54 | 0.74-3.20 | 0.24 |
| Alcoholism | ||||
| No | 1 | 1 | ||
| Yes | 0.44 | 1.55 | 1.04-2.30 | 0.03 |
| Gender | ||||
| Female | 1 | 1 | ||
| Male | 1.87 | 6.49 | 1.46-28.80 | 0.01 |
| Age | 0.02 | 1.02 | 0.99-1.04 | 0.08 |
| Clinical form | ||||
| Extrapulmonary | 1 | 1 | ||
| Pulmonary | 0.01 | 1.01 | 0.67-1.52 | 0.97 |
| TB/HIV coinfection and gender | ||||
| Without coinfection and female | 1 | 1 | ||
| With coinfection and male | −1.14 | 0.32 | 0.13-0.78 | 0.01 |
| Age and gender (male) | −0.03 | 0.97 | 0.94-0.99 | 0.03 |
Mixed-effect model of the associated factors with precocious deaths due tuberculosis, Curitiba-Brazila
| Estimate | Std. error | Odds ratio | 95% CI | ||
|---|---|---|---|---|---|
| 0.94 | 2.98 | 0.75 | |||
| Relapse | −4.71 | 1.85 | <0.01 | 0.01-0.34 | 0.01** |
| Yes | −1.99 | 1.47 | 0.13 | 0.01-2.44 | 0.17 |
| Yes | 2.88 | 1.39 | 17.93 | 1.16-276.58 | 0.03** |
| Male | −2.32 | 1.51 | 0.09 | 0.005-1.89 | 0.12 |
| 004 | 0.04 | 1.04 | 0.95-1.14 | 0.34 | |
| Pulmonary | 0.63 | 1.39 | 1.87 | 0.12-28.99 | 0.65 |
| 2.35 | 0.66 | 3.58 | 2.89-10.48 | <0.01** | |
**p value <0.05
aPower of test—54.00% (95% CI 39.32; 68.19) based on 50 Monte Carlo simulation